Yesterday, after the market has opened, the stock rocketed from $1.421 to $1.69, indicating the greatest value of $1.79. Today, after the market opened, the stock stands volatile at approximately $1.69. What is affecting the change?
As previously announced, for Cohort 1, we administered one dose of the investigational new drug IGC-AD1 per day to trial participants. We increased the dosage to two doses of IGC-AD1 per day in Cohort 2, which was conducted from early February 2021 through mid-May 2021. The Phase 1 clinical trial on Alzheimer’s patients is currently anticipated to conclude during the July through September 2021 timeframe.
The company’s shares are expected to skyrocket because of the study’s effectiveness, repeating the performance of February 10, 2021, leading the stock to an astonishing $3.1. Is it worthwhile to invest in such companies? This is undoubtedly a risk, but if the investor believes in the enterprise, it may turn out to be a significant benefit in the long term.